Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.

Huang, Jing-Feng; Yafawi, Rolla; Zhang, Min; McDowell, Michael; Rittenhouse, Kay D; Sace, Frederick; Liew, Shiao Hui Melissa; Cooper, Scott R; Pickering, Eve H

Huang, Jing-Feng; Yafawi, Rolla; Zhang, Min; McDowell, Michael; Rittenhouse, Kay D; Sace, Frederick; Liew, Shiao Hui Melissa; Cooper, Scott R; Pickering, Eve H.

Affiliation

Huang JF; Pfizer Inc, San Diego, California, USA. jingfenghuang@yahoo.com

Ophthalmology ; 119(7): e43-50, 2012 Jul.

Article in En | MEDLINE | ID: mdl-22607938

Subject(s)

Dry Eye Syndromes/drug therapy; Janus Kinase 3/antagonists & inhibitors; Pyrimidines/administration & dosage; Pyrroles/administration & dosage; Administration, Topical; Conjunctiva/metabolism; Cyclosporine/administration & dosage; Cytokines/metabolism; Dry Eye Syndromes/metabolism; Female; Flow Cytometry; HLA-DR1 Antigen/metabolism; Humans; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Tears/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Pyrroles / Dry Eye Syndromes / Janus Kinase 3 Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Ophthalmology Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google